Study guide
11.3 Motivational Interviewing and Shared Decision-Making
PEBC Pharmacist Evaluating Examination Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Introduction & The Canadian Pharmacy Practice Landscape
1.1 PEBC EE Blueprint, Format, Scoring, and IPG Certification Pathway 1.2 The Canadian Healthcare System, Canada Health Act, and Drug Regulation 1.3 Canadian Pharmacy Regulatory Framework, NAPRA Standards, and Professional Legislation
2 Chapter 2: Pharmaceutics & Drug Delivery Systems
2.1 Physicochemical Principles, Solubility, Ionization, and Stability 2.2 Solid Dosage Forms, Formulation Science, and Modified-Release Technologies 2.3 Liquid and Semisolid Dosage Forms, Dispersions, and Topical Delivery 2.4 Sterile Product Principles, Parenteral Delivery, and Biopharmaceuticals 2.5 Pharmaceutical Quality: GMP, Stability Testing, and Bioequivalence
3 Chapter 3: Biopharmaceutics & Clinical Pharmacokinetics
3.1 Drug Absorption, Distribution, Metabolism, and Elimination (ADME) 3.2 Bioavailability, Bioequivalence, and Biopharmaceutics Classification System (BCS) 3.3 Pharmacokinetic Modeling, Parameters, and Dosing Calculations 3.4 Therapeutic Drug Monitoring (TDM) and Clinical Application
4 Chapter 4: Pharmacology, Toxicology & Pharmacogenetics
4.1 Autonomic and Central Nervous System Pharmacology 4.2 Cardiovascular, Renal, and Endocrine Pharmacology 4.3 Clinical Toxicology, Overdose Management, and Antidotes 4.4 Biologics, Biosimilars, and Pharmacogenetics
5 Chapter 5: Pathophysiology & Clinical Assessment
5.1 Clinical Laboratory Diagnostics, Biomarkers, and Vital Signs 5.2 Cardiovascular and Respiratory Pathophysiology 5.3 Endocrine, Renal, and Gastrointestinal Pathophysiology 5.4 Neurologic, Psychiatric, and Musculoskeletal Pathophysiology 5.5 Physical Assessment and Point-of-Care Testing
6 Chapter 6: Pharmacotherapy & Minor Ailments
6.1 Cardiovascular Pharmacotherapy & Evidence-Based Guidelines 6.2 Endocrine and Metabolic Pharmacotherapy 6.3 Infectious Diseases and Antimicrobial Stewardship 6.4 Neurologic, Psychiatric, and Pain Management Therapeutics 6.5 Minor Ailment Prescribing and Nonprescription Therapy 6.6 Respiratory Pharmacotherapy: Asthma, COPD, and Inhaled Therapy 6.7 Gastrointestinal and Hepatic Pharmacotherapy 6.8 Renal, Fluid, and Electrolyte Therapeutics 6.9 Musculoskeletal and Rheumatologic Pharmacotherapy 6.10 Dermatologic, Ophthalmic, and Ear-Nose-Throat Pharmacotherapy 6.11 Hematologic, Immunologic, and Oncology Supportive Care 6.12 Women's Health, Men's Health, and Urologic Therapeutics 6.13 Nutrition, Natural Health Products, and Complementary Medicine
7 Chapter 7: Special Populations & Applied Therapeutics
7.1 Geriatric Pharmacotherapy and Deprescribing 7.2 Pediatric and Neonatal Pharmacotherapy 7.3 Perinatal Pharmacotherapy: Pregnancy and Lactation 7.4 Dosage Adjustments in Renal and Hepatic Impairment
8 Chapter 8: Prescription Processing, Calculations & Compounding
8.1 Prescription Processing, Verification, and Drug Therapy Problem Management 8.2 Pharmaceutical Calculations and Clinical Math 8.3 Non-Sterile Compounding and NAPRA Standards 8.4 Sterile and Hazardous Compounding under NAPRA Standards 8.5 Advanced Calculations: Infusion Rates, Parenteral Nutrition, and Renal Estimation
9 Chapter 9: Health Equity, Indigenous Health & Pharmacy Bioethics
9.1 Social Determinants of Health and Health Equity 9.2 Indigenous Health, Cultural Safety, and Humility 9.3 Pharmacy Bioethics, Informed Consent, and Professional Boundaries 9.4 Health Promotion, Disease Prevention, and Public Health
10 Chapter 10: Evidence Appraisal, Safety & Practice Management
10.1 Biostatistics and Critical Appraisal of Clinical Literature 10.2 Pharmacoeconomics and Pharmacoepidemiology 10.3 Medication Safety, Incident Analysis, and Quality Improvement 10.4 Pharmacy Operations, Cold-Chain Management, and Emergency Preparedness 10.5 Drug Information and Evidence-Based Decision Making 10.6 Pharmacovigilance and Adverse Drug Reaction Reporting in Canada
11 Chapter 11: Patient Care Process, Communication & Collaborative Practice
11.1 The Patient Care Process: Assessment, Care Plans, and Follow-Up 11.2 Patient and Caregiver Communication, Education, and Health Literacy 11.3 Motivational Interviewing and Shared Decision-Making 11.4 Intra- and Interprofessional Collaborative Care
12 Chapter 12: Medication Administration, Devices & Expanded Scope
12.1 Injection and Vaccine Administration Technique 12.2 Immunization Schedules, Vaccine Selection, and Travel Health 12.3 Home Medical Devices and Device Technique Coaching 12.4 Expanded Scope: Adapting, Renewing, Initiating, and Medication Reconciliation
13 Chapter 13: Pharmacy Management, Finance & Practice Leadership
13.1 Human Resources, Leadership, and Change Management 13.2 Financial Management, Drug Plans, and Marketing 13.3 Quality Improvement, Risk Management, and Workplace Safety
11.3 Motivational Interviewing and Shared Decision-Making
Key Takeaways Explain This Topic AI
Motivational interviewing resolves ambivalence by evoking the patient's own reasons for change rather than supplying the pharmacist's reasons.
The core skills are summarised as OARS: open questions, affirmations, reflective listening, and summaries.
The righting reflex — the urge to correct and persuade — reliably increases resistance and reduces the likelihood of change.
Shared decision-making applies when there is genuine equipoise, and requires that the patient understands the options, the benefits and harms, and the uncertainty.
Non-adherence is usually a mix of intentional and unintentional causes, and the intervention must match the cause rather than defaulting to more information.
Last updated: August 2026
11.3 Motivational Interviewing and Shared Decision-Making
Exam Focus: The PEBC syllabus lists motivational interviewing and shared decision-making as distinct bullets. Examination items usually present a patient who is reluctant or undecided and ask which pharmacist response is most likely to help.
Motivational Interviewing
Motivational interviewing is a collaborative, goal-oriented conversational method for strengthening a person's own motivation and commitment to change. It was developed for substance use and now applies across adherence, smoking cessation, weight, and chronic disease self-management.
The spirit: partnership, acceptance, compassion, evocation
The approach rests on the premise that motivation cannot be installed from outside. The pharmacist's task is to evoke what is already there — the patient's own values and reasons — rather than to supply arguments.
The righting reflex
The righting reflex is the trained clinician's urge to correct what appears wrong: to explain the risks harder, to list the consequences, to persuade. It predictably produces the opposite of what is intended. When one person argues for change, the ambivalent person argues against it, hears themselves defend the status quo, and becomes more committed to it. Suppressing the righting reflex is the single most important behaviour change for the practitioner.
OARS: the core skills
- Skill What it is Example
- O — Open questions Invite elaboration "What would need to be different for you to consider taking it daily?"
A — Affirmations Recognise genuine strengths and effort "You've kept the appointments even during a hard month — that takes real effort."
R — Reflective listening Restate meaning, sometimes amplified "You want the blood pressure down, and you don't want to feel dizzy at work."
S — Summaries Collect and organise what was said "So the cost is manageable, the timing is not, and the dizziness worries you most."
Change talk and sustain talk
Change talk is any patient speech favouring change. Listen for and reinforce it using the acronym DARN-CAT : D esire ("I want to"), A bility ("I could"), R eason ("it would help my knees"), N eed ("I have to"), then the mobilising forms — C ommitment ("I will"), A ctivation ("I'm ready to"), and T aking steps ("I bought a pill organiser").
Sustain talk favours the status quo. It is not defiance; it is one half of ambivalence. Reflect it without arguing, then ask what sits on the other side.
Two practical tools:
Scaling questions. "On a scale of 0 to 10, how important is it to you to stop smoking?" If the answer is 4, ask "Why a 4 and not a 2?" — which elicits the patient's own reasons for change. Asking "why not an 8?" evokes sustain talk and is the common error.
Elicit-provide-elicit. Ask permission and find out what the patient already knows, provide the information neutrally, then ask what they make of it. This delivers advice without triggering resistance.
Shared Decision-Making
Shared decision-making is the process by which a clinician and patient reach a healthcare decision together, combining the best available evidence with the patient's values and preferences. It is indicated when there is genuine equipoise — more than one reasonable option, including doing nothing — which describes most preference-sensitive decisions in pharmacy: anticoagulation in atrial fibrillation, statin therapy in primary prevention, bisphosphonate duration, or deprescribing.
A workable three-step structure:
Choice talk — make it explicit that a choice exists. "There is more than one reasonable option here, and what matters most to you should shape which one we pick."
Option talk — describe each option with its benefits and harms in natural frequencies over a stated time horizon, including the option of no treatment, and name the uncertainty.
Decision talk — explore what matters most to the patient, support deliberation, and reach a decision, allowing time where the decision is not urgent.
Shared decision-making is not the same as informed consent, though it supports it, and it is not the abandonment of professional recommendation. The pharmacist may still say what they would suggest and why; what changes is that the patient's values are treated as evidence about what a good outcome looks like for them.
Decision aids — printed or digital tools presenting options, outcome probabilities, and value clarification exercises — measurably improve knowledge, produce more accurate risk perception, and reduce decisional conflict.
Diagnosing Non-Adherence Before Intervening
Roughly half of patients with chronic conditions do not take long-term therapy as prescribed. Effective intervention depends on identifying the cause.
Type Cause Matched intervention
Unintentional Forgetting, complex regimen, dexterity or vision limits, cost, access Simplify and align doses, blister packs or organisers, reminders, easier devices, coverage assistance, synchronised refills
Intentional Belief the drug is unnecessary or harmful, adverse effects, conflicting values, previous bad experience Explore beliefs, address the specific concern, negotiate a trial with agreed monitoring, adjust therapy
Providing more information helps only unintentional non-adherence caused by a knowledge gap. Giving a patient who has stopped a statin because of muscle pain a leaflet about cholesterol addresses nothing. Asking non-judgementally is the first step: "Most people miss doses sometimes. In the last week, how many times did you miss the tablet, and what usually gets in the way?"
The necessity-concerns framework is a useful lens: adherence rises when the patient's perceived necessity for the medicine exceeds their concerns about it. An intervention can therefore work by strengthening perceived necessity, by reducing a specific concern, or both.